Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Piminodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.60 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.60 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piminodine SCHEMBL676858 | 0.97 | KCNA3 (0.64) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Piminodine SCHEMBL26477 | 0.96 | KCNA3 (0.71) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11708747 | 0.82 | KCNA3 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL6197539 | 0.80 | KCNA3 (0.77) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.80 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.79 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL9064512 | 0.79 | OPRM1 (0.75) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11601769 | 0.79 | OPRM1 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL9064841 | 0.78 | KCNA3 (0.73) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712071 | 0.78 | OPRM1 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313892-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN ASSOCIATED WITH DYSMENORRHEA | TRINITY LAB INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-20140134261-A1 | Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores | TRINITY LABORATORIES, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20130189354-A1 | Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy | Trinity Laboratories, Inc., (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012048294-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | TRINITY LABORATORIES, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-7645767-B2 | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy | TRINITY LABORATORIES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090312361-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS FOR TREATING ACQUIRED CHRONIC PAIN AND ASSOCIATED DYSPHORIA | STREEPER ROBERT T | 2009-12-17 | — | — | US | disclosed |
| US-20080176873-A1 | Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria | TRINITY LABORATORIES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080058362-A1 | Novel pharmaceutical compositions for treating chronic pain and pain associated with neuropathy | JEFFERSON BANK | 2008-03-06 | — | — | US | disclosed |
| WO-2006053012-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS FOR TREATING ACQUIRED CHRONIC PAIN AND ASSOCIATED DYSPHORIA | TRINITY LABORATORIES, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134261-A1 | Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores | TRPV1, ALOX12, OPRK1 | SLC6A4 2444/4885ADRA1A 255/4885KCNA3 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.